BLUEHOLE-NEW-CONSUMPTION
14.3.2022 07:50:03 CET | Business Wire | Press release
China’s leading vaping media, Bluehole New Consumption, today publishes an industry comment on China's First Corporate Risk Assessment Laboratory for the European Union Tobacco Products Directive Compliance.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220313005043/en/
Here below is the full article:
SMOORE, a global leader in offering vaping technology solutions, today announced an industry-leading risk assessment laboratory for the European Union Tobacco Product Directive (EUTPD) compliance. Thus, SMOORE has become China's first company capable of providing vaping products with one-stop TPD risk assessment service. Belonging to SMOORE fundamental research center, the laboratory will be a hub to empower more vaping brands to comply with the safety standards of EUTPD, thereby meeting the EU vaping market entry requirements.
This laboratory has begun operation in the first half of 2021, and already completed 52 product tests for several world-leading vape brands. As China’s first corporate TPD-compliant risk assessment laboratory, it can generate test reports within 5 working days. Its laboratory equipment is benchmarked against those in world-class analytical testing laboratories, such as Labstat and Enthalpy.
Entering into force in 2014, the TPD is a unified directive for tobacco regulations in the 27 EU Member States. It regulates the sale, presentation and manufacture of all tobacco products, including e-cigarettes, in the EU. For the sake of quality control and public health protection, the TPD sets specific safety requirements for the content of e-cigarettes, such as nicotine concentration, heavy metals, carbonyl, Aldehydes and Ketones, for the products allowed to be placed on the EU market.
As the second largest market for vaping products after North America, Europe has over 16.74 million adult vapors in 2022, with a market size of USD 5.58 billion (ECigIntelligence). Furthermore, the regional vaping market size is projected to witness a CAGR of 13.17% in the next 6 years.
With only one e-cigarette (Vuse Solo) approved by the U.S. FDA through the Premarket Tobacco Product Application (PMTA) pathway so far, more and more vape brands are aiming for European market, considering its relatively friendly regulatory environment and significant market potential.
As the industry's harm reduction and quality benchmark, SMOORE complies with its in-house SMOORE 3.0 safety standards. Based on the risk assessment guidance of U.S. EPA (Environmental Protection Agency) and PMTA, SMOORE 3.0 covers all of the PMTA vapor safety tests and HPHCs (Harmful and Potentially Harmful Constituents) listed by U.S. FDA. In addition to vapor safety, SMOORE 3.0 also involves extractable and leachable substances of medical-grade atomization materials.
SMOORE fundamental research center has developed a comprehensive analytical testing and risk assessment system, covering PMTA non-clinical testing and health risk assessment. Accredited by China National Accreditation Service for Conformity Assessment (CNAS) in 2019, now it is capable of up to 149 CNAS tests, involving the chemical analysis of e-liquids and aerosols, electrical safety, material safety and battery safety.
Since FEELM, the flagship atomization tech brand belonging to SMOORE, entered the EU market in 2018, SMOORE has been in partnership with several leading vape brands in this region, including Vuse, HEXA, Innocigs and Alfapod. To date, vaping products loaded with FEELM technologies have been exported to Belgium, Netherlands, Estonia, and Romania, with market leadership in the UK, Germany and France.
To read the original article, please visit: https://www.bluehole.com.cn/news/detail/48728
View source version on businesswire.com: https://www.businesswire.com/news/home/20220313005043/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
REPLY: The Board of Directors Approved the Draft Financial Statements for the Year 202512.3.2026 15:38:00 CET | Press release
All economic indicators are positive.Consolidated turnover of €2,483.6 million (€2,300.5 million in 2024);EBITDA at €467.6 million (€410.6 million in 2024);EBIT at €391.7 million (€330.4 million in 2024)Group net profit at €250.9 million (€211.1 million in 2024)Approval of the proposed dividend distribution of €1.35 per share. Today the Board of Directors of Reply S.p.A. [MTA, STAR: REY] approved the draft financial statement for the year 2025, which will be submitted for approval to the Shareholders’ Meeting to be held in first call in Turin on 23 April 2026. The Reply Group closed 2025 with a consolidated turnover of €2,483.6 million, an increase of 8.0% compared to €2,300.5 million in 2024. All indicators are positive for the period. Consolidated EBITDA was €467.6 million, an increase of 13.9% compared to €410.6 million at December 2024. EBIT, from January to December, was at €391.7 million, which is an increase of 18.5% compared to €330.4 million at December 2024. The Group net pro
LZE GmbH Introduces Fraunhofer’s RFicient® Technology to the Market12.3.2026 14:51:00 CET | Press release
LZE GmbH is expanding its technology transfer portfolio and making the RFicient® ultra-low-power wake-up receiver technology from the Fraunhofer Institute for Integrated Circuits IIS available for the first time as a standard chip for close-to-production industrial applications. The solution enables energy-efficient IoT designs that remain continuously reachable while consuming only microamps – a key step for long-lasting, low-maintenance IoT products. LZE GmbH drives technology transfer to market: standard chip availability for close-to-production applications As a bridge between research and industry, LZE GmbH is making it easier for companies to access innovative technologies and helping them to quickly and reliably transform new developments into market-ready solutions. With RFicient®-IC (FH101RF), LZE is providing another high-tech product that comes directly from Fraunhofer research and can now be ordered in volume and integrated into close-to-production product development for t
Owkin Creates New Spin out Waiv, Formerly Owkin Dx, With $33M Financing12.3.2026 14:30:00 CET | Press release
Investment lead by OTB Ventures and Alpha Intelligence CapitalWaiv develops AI-powered precision testing to better identify and stratify patients in the clinic and in clinical trials, transforming patient careWaiv extends Owkin’s strategy of real-world validation for its AI Owkin, the AI company on a mission to solve the complexity of biology, today announced the spin out of Waiv, formerly known as Owkin Dx. The move follows significant investor interest and positions Waiv to bring AI-powered precision testing for better identification of patients in the clinic and in clinical trials, to transform patient care. This follows on from the successful launch of Bioptimus, an Owkin incubated company, in February 2024. Waiv translates AI innovation into real-world clinical impact, developing tests that predict biomarkers and patient outcomes, including RlapsRisk BC for prognostic risk profiling. With multiple tests already in use in clinical settings, its deployment platform Destra, and colla
RQM+ Launches SMART Solutions Life Cycle Partnership Model12.3.2026 14:30:00 CET | Press release
Helps MedTech Companies Navigate MDR, IVDR, and AI-Enabled Device Development RQM+, a leading MedTech CRO offering regulatory consulting, clinical trial, laboratory, and reimbursement services, today announced the launch of SMART Solutions, a life cycle partnership model designed to help medical device and diagnostics companies manage growing regulatory and development complexity. SMART Solutions introduces a strategy-led operating framework that unifies regulatory, quality, clinical, reimbursement, and laboratory expertise to support MedTech companies across the entire product life cycle to help reduce risk from early development through post-market. “MedTech companies are navigating unprecedented complexity as regulatory expectations evolve, product innovation accelerates, and post-market expectations are expanding,” said John Potthoff, Ph.D., chief executive officer of RQM+. “SMART Solutions moves beyond traditional consulting by providing an integrated life cycle partnership that h
Cryptio Raises $45m Series B as Digital Assets Move Into Regulated Financial Markets12.3.2026 14:06:00 CET | Press release
The system of record for tokenized finance – ERP infrastructure for institutions operating in digital assets Cryptio, a leader in financial data transformation and enterprise resource planning (ERP) applications for regulated digital assets, announced today a $45 million Series B funding round co-led by BlackFin Capital Partners and Sentinel Global, with participation from 1kx, Alven, BlueYard Capital and Ledger Cathay Capital. Banks, exchanges, asset managers, including Société Générale’s SG Forge, Circle, Gemini, and Securitize rely on Cryptio to ensure financial integrity across their digital assets businesses. Existing ERP systems fall short for digital assets Traditional ERP and accounting systems were not designed for blockchain-native assets, real-time reporting, or modern custody frameworks. As regulated financial institutions expand into stablecoins, tokenized securities and other on-chain instruments, these limitations create material operational and reporting challenges. Cry
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
